Meningococcal Infections clinical trials
The registry lists 243 studies for Meningococcal Infections across more than 10 countries. 8 are recruiting or about to start. 159 of them are mainly about Meningococcal Infections (how this is decided). Per ClinicalTrials.gov, last updated 2026-10-21. Counting its narrower condition Meningitis, Meningococcal too: 309 studies, 17 open.
Get an email when these change. Save the Meningococcal Infections studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
GlaxoSmithKline (71) · Sanofi Pasteur, a Sanofi Company (53) · Novartis Vaccines (51) · Novartis (9) · Pfizer (7) · Public Health England (4) · Sanofi (4) · University of Oxford (4)
What is being tested here
Drugs under test in Meningococcal Infections studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
The study
Who these studies take
Of the 7 Meningococcal Infections studies recruiting now, 3 (43%) set no upper age limit and 4 (57%) stop at 75 or younger. 4 (57%) take children under 18. 1 (14%) are for women only and 0 (0%) for men only; 6 (86%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 3 (43%) | 2 (29%) |
| 18 | 5 (71%) | 4 (57%) |
| 30 | 5 (71%) | 5 (71%) |
| 40 | 5 (71%) | 5 (71%) |
| 50 | 5 (71%) | 5 (71%) |
| 65 | 3 (43%) | 3 (43%) |
| 75 | 3 (43%) | 3 (43%) |
| 85 | 3 (43%) | 3 (43%) |
Across all 243 studies, recruiting or not: 87% stop at 75 or younger and 86% at 65; 84% take children; 2% are for women only and 0% for men only; 93% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
How long Meningococcal Infections studies take
Of 46 phase 3 interventional studies under Meningococcal Infections, half reached primary completion within 15 months of starting, counting those still running.
| Start to primary completion | Every sponsor | Industry | Non-industry |
|---|---|---|---|
| Phase 2 | 10 mo7–17 · 18 studies | — | — |
| Phase 3 | 15 mo8–40 · 46 studies | 15 mo8–40 · 46 studies | — |
| Phase 4 | 34 mo23–45 · 12 studies | — | — |
Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out
What changed recently
From the registry's own updates since Oct 13, 2026.
Studies
Recruiting first, then most recently updated. Showing 50 of 243. Browse all 243 → or search them.
- Single-center, Open-label Study: Immunogenicity and Safety Observation After Vaccination With ACYW135 Meningococcal Polysaccharide Vaccine in Junior High School Students Aged 13-15 YearsNot yet recruitingNCT07885371Phase 4
- Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Infants and Toddlers in ChinaRecruitingNCT07710872Phase 31 country
- A Study to Learn About the Safety of PENBRAYA During PregnancyRecruitingNCT077681631 country
- Observational, Passive Surveillance Program to Collect Information on Women and Their Offspring Exposed to MenQuadfi® During Pregnancy, in United States (US)RecruitingNCT048431111 country
- Immunogenicity and Safety of Meningococcal Conjugate Vaccine (EG-MCV4) in Healthy Adults Aged 19 to 55 Years OldRecruitingNCT07204457Phase 2/31 country
- Meningococcal B Vaccine in Patients with AspleniaRecruitingNCT06025487Phase 21 country
- Epidemiological, Clinical and Biological Caracteristics of Patients Presenting With Invasive Meningococcal DiseaseRecruitingNCT059815991 country
- Safety and Immunogenicity Following Meningococcal and Pneumococcal Immunization Among Adult People Living With HIVRecruitingNCT04875819Phase 41 country
- Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Children and Adolescents in ChinaCompletedNCT07135986Phase 31 country
- Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy InfantsCompletedNCT03621670Phase 32 countries
- A Study on the Safety, Tolerability and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy InfantsCompletedNCT05082285Phase 28 countries
- Azithromycin for Meningococcal CarriageCompletedNCT06618534Phase 21 country
- Understanding the Immune Response to Two Different Meningitis VaccinesCompletedNCT01593514Phase 41 country
- A Study on the Immune Response and Safety of a Vaccine Against N. Meningitidis Serogroup B Infection in Healthy Infants From 2 Months of AgeActive, not recruitingNCT06113198Phase 41 country
- Study on a MenACYW Conjugate Vaccine Administered as a Single Dose in Participants Aged 12 Months and Older in VietnamCompletedNCT06228586Phase 31 country
- Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine in Older Adults Who Received a Primary Vaccination (3 or More Years Earlier) in Study MET49CompletedNCT04142242Phase 32 countries
- A Study on the Safety, Effectiveness and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Adolescents and AdultsCompletedNCT04886154Phase 1/28 countries
- Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) in Older Adults in Turkey and LebanonCompletedNCT03869866Phase 32 countries
- Study to Assess the Safety and Immunogenicity of GSK Meningococcal Group B Vaccine When Administered Concomitantly With GSK Meningococcal MenACWY Conjugate Vaccine in Healthy Subjects of 16-18 Years of AgeCompletedNCT04318548Phase 32 countries
- Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in EuropeCompletedNCT03547271Phase 37 countries
- Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the USCompletedNCT03537508Phase 32 countries
- Immunogenicity and Safety Study of GSK's MenABCWY Vaccine in Healthy Adolescents and Adults Previously Primed With MenACWY VaccineCompletedNCT04707391Phase 34 countries
- Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and ToddlersCompletedNCT03691610Phase 32 countries
- Effectiveness of GlaxoSmithKline Biologicals S.A's Meningococcal Group B and Combined ABCWY Vaccines in Healthy Adolescents and Young AdultsCompletedNCT04502693Phase 37 countries
- Safety and Immunogenicity of Pentavalent Meningococcal Conjugate Vaccine (EuNmCV-5) in Healthy Adults Aged 19 to 55 Years OldCompletedNCT05739292Phase 11 country
- Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and ToddlersCompletedNCT03673462Phase 32 countries
- MenPF-1 - A New Vaccine Against Meningococcal DiseaseCompletedNCT01640652Phase 11 country
- Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine in Infants and Toddlers When Administered Concomitantly With Routine Pediatric Vaccines in the United KingdomCompletedNCT03632720Phase 31 country
- Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the Russian Federation and MexicoCompletedNCT03630705Phase 32 countries
- Septic cArdiac Deficiency and MenIngococcal seveRe SepsisCompletedNCT02041663Not applicable1 country
- A Sourcing Study to Collect Human Blood Samples From Healthy AdultsCompletedNCT03493919Phase 42 countries
- Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Children, Adolescents and Adults in RussiaCompletedNCT01725217Phase 31 country
- The Long-term Impact of Invasive Meningococcal Disease in Australian Adolescents and Young AdultsCompletedNCT037985741 country
- Immunisation for Adolescents Against Serious Communicable Diseases (B Part of it NT)Status unknownNCT043988491 country
- Observational Safety Study of Menactra® Administered Under Standard Health Care Practice in the Russian FederationCompletedNCT026998401 country
- Postmarketing Surveillance Study for Use of Menactra® in the Republic of KoreaCompletedNCT02864927Phase 41 country
- Immunogenicity and Safety of Menactra® Vaccine in Subjects Aged 9 to 23 Months in India and in the Russian FederationCompletedNCT01890759Phase 32 countries
- Enhanced Population-based Core Surveillance of Meningococcal Invasive Infections at Participating Centers Across CanadaStatus unknownNCT041843361 country
- Immunogenicity and Safety of a Booster Dose of a Quadrivalent Meningococcal Conjugate Vaccine in ChildrenCompletedNCT03476135Phase 31 country
- Immunogenicity and Safety of a Meningococcal Conjugate Vaccine Given Concomitantly With Other Vaccines in ToddlersCompletedNCT03205371Phase 34 countries
- Immunogenicity and Safety of a Booster Dose of an Investigational Quadrivalent Meningococcal Conjugate VaccineCompletedNCT02752906Phase 32 countries
- Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adults 56 Years and OlderCompletedNCT02842866Phase 32 countries
- Immune Lot Consistency, Immunogenicity, and Safety of an Investigational Quadrivalent Meningococcal Conjugate VaccineCompletedNCT02842853Phase 31 country
- Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in ToddlersCompletedNCT02955797Phase 34 countries
- Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy ToddlersCompletedNCT03205358Phase 21 country
- Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy AdolescentsCompletedNCT02199691Phase 22 countries
- Study of a Quadrivalent Meningococcal Conjugate Vaccine in Subjects Aged 56 and OlderCompletedNCT01732627Phase 21 country
- Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Children Aged 2 to 9 YearsCompletedNCT03077438Phase 32 countries
- A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and ToddlersCompletedNCT01049035Phase 21 country
- A Surveillance Study on Timing and Coverage Of Rotavirus and MenB Vaccine Co-administration in Campania Region, ItalyStatus unknownNCT05212935